Oxea Receives Product Leadership Award for its Phthalate-free Plasticizer Product Range

Based on its recent analysis of the European plasticizers market, Frost & Sullivan has recognized chemical company Oxea with the ‘2014 European Non-Phthalate Plasticizers Product Leadership Award'.

The researchers lauded Oxea for its consistent high product quality, performance, and supply reliability as well as for continuous product development and innovation. Oxea produces Oxsoft and Oxblue, two comprehensive product ranges of phthalate-free and bio-based plasticizers that meet customer demands for regulatory compliance and safety. They meet and exceed performance requirements of conventional phthalate plasticizers, which they replace. 

"We are proud to receive this recognition from the industry. As a pioneer in the industry, Oxea early on invested into the development of phthalate-free plasticizers. Focused research and our ability to quickly bring new products to market made it possible to flexibly address the requirements of the markets," commented Jacco de Haas, Global Marketing Manager for Specialty Esters at Oxea. "New products are already under development and we will continue to invest into more capacity to serve our customer's needs," he continued.

"Oxea has demonstrated commitment to differentiation and competence in the European plasticizers market," said Srinivas Venkatesan, Research Associate with Frost & Sullivan. "Oxea's relentless customer-centric approach in all activities from product development to product delivery and service, coupled with its backward integration into raw material manufacturing and ensuring timely delivery of products to customers has propelled the company to the forefront of European plasticizers market. With its strong overall performance, Oxea has earned Frost & Sullivan's 2014 Product Leadership Award," noted Venkatesan.

 

 

 

Company

Logo:

Oxea

Rheinpromenade 4a
40789 Monheim am Rhein
Germany

Company contact







Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
19.03.2025 • TopicsStrategy

Substances of Concern

The EU Chemicals Strategy for Sustainability (CSS) highlights the shift to a hazard-centric approach in EU chemical regulation, emphasizing 'Substance of Concern' over risk-based measures.

Photo
14.05.2025 • TopicsPharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.